Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose 131I-MIBG with Topotecan and PBSC for Neuroblastoma
NCT00389766Phase 2Withdrawn
- Sponsor
- Children's Cancer and Leukaemia Group
- Start
- Jul 2008
- Primary completion
- Jul 2008
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of Iobenguane I-131 in neuroblastoma, sponsored by Children's Cancer and Leukaemia Group. Primary endpoints: Proportion of patients who respond to treatment (partial response and complete response at metastatic sites), Proportion of patients who are able to progress to potentially curative treatment with surgery and further systemic treatment and 2 more. Planned start Jul 2008; status: withdrawn.
02
Drugs
Iobenguane I-131
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00389766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00389766.